---
figid: PMC6328535__41598_2018_37188_Fig6_HTML
figtitle: Dacarbazine and PLX4032 cross-resistance emerges via distinct MAPK-dependent
  and -independent pathway activation
organisms:
- Homo sapiens
- Armoracia rusticana
pmcid: PMC6328535
filename: 41598_2018_37188_Fig6_HTML.jpg
figlink: /pmc/articles/PMC6328535/figure/Fig6/
number: F6
caption: Dacarbazine and PLX4032 cross-resistance emerges via distinct MAPK-dependent
  and -independent pathway activation. Canonical and oncogenic MAPK and PI3K/AKT/mTOR
  signalling in (A) parental, sensitive BRAFV600E melanoma cells, (B) dacarbazine-resistant
  BRAFV600E melanoma cells that show cross-resistance to vemurafenib (PLX4032) and
  (C) PLX4032-resistant BRAFV600E melanoma cells that have cross-resistance to dacarbazine.
  BRAFV600E affected, hyperactivated kinases are marked in red, dacarbazine- and PLX4032-affected
  molecular targets of resistance emergence are marked in green and blue, respectively.
  GPCR = G-protein-coupled receptor, RTK = receptor tyrosine kinase, GFs = growth
  factors.
papertitle: Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic
  dacarbazine after chronic PLX4032 treatment.
reftext: Sarah Erdmann, et al. Sci Rep. 2019;9:30.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9443591
figid_alias: PMC6328535__F6
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6328535__F6
ndex: 257a854c-de8e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6328535__41598_2018_37188_Fig6_HTML.html
  '@type': Dataset
  description: Dacarbazine and PLX4032 cross-resistance emerges via distinct MAPK-dependent
    and -independent pathway activation. Canonical and oncogenic MAPK and PI3K/AKT/mTOR
    signalling in (A) parental, sensitive BRAFV600E melanoma cells, (B) dacarbazine-resistant
    BRAFV600E melanoma cells that show cross-resistance to vemurafenib (PLX4032) and
    (C) PLX4032-resistant BRAFV600E melanoma cells that have cross-resistance to dacarbazine.
    BRAFV600E affected, hyperactivated kinases are marked in red, dacarbazine- and
    PLX4032-affected molecular targets of resistance emergence are marked in green
    and blue, respectively. GPCR = G-protein-coupled receptor, RTK = receptor tyrosine
    kinase, GFs = growth factors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - RAF1
  - BRAF
  - MAP3K8
  - CROT
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - PDGFRA
  - dacarbazine
  - PLX4032
  - vemurafenib
  - dacarbazine H
  - Cancer
---
